Jan 13, 2026 08:00AM

Jan 13, 2026 08:00AM

Jan 13, 2026 07:58AM

Jan 13, 2026 07:58AM

Sep 9, 2024 06:42AM

Jun 26, 2024 09:05AM

Jun 26, 2024 09:05AM Oramed Letter to Shareholders

Mar 19, 2024 09:01AM

Mar 19, 2024 09:00AM

Feb 20, 2024 08:31AM

Feb 20, 2024 08:30AM

Sep 21, 2023 04:07PM

Sep 21, 2023 04:05PM

Sep 13, 2023 09:02AM Scilex Holding (SCLX) Enters Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento

Sep 13, 2023 09:00AM

May 15, 2023 09:07AM

Dec 21, 2022 08:25AM

Dec 21, 2022 08:25AM

Nov 18, 2022 05:17AM

Nov 18, 2022 04:11AM

Nov 10, 2022 04:30PM Oramed Reports Third Quarter 2022 Financial Results

Jul 26, 2022 07:56AM

Jul 26, 2022 07:55AM

Jul 7, 2022 07:56AM

Jul 7, 2022 07:55AM

Jun 1, 2022 07:55AM

May 3, 2022 08:10AM

Mar 22, 2022 08:25AM Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Jan 12, 2022 08:45AM

Dec 29, 2021 09:17AM

Dec 29, 2021 09:15AM

Nov 23, 2021 08:25AM

Nov 18, 2021 09:17AM

Nov 18, 2021 09:15AM

Aug 24, 2021 08:25AM Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

Aug 10, 2021 10:31AM

Aug 10, 2021 10:30AM

Jun 8, 2021 08:10AM

May 25, 2021 08:44AM

May 25, 2021 08:40AM

Mar 23, 2021 09:28AM

Mar 23, 2021 09:00AM Oramed Pharma (ORMP) Begins Second Phase 3 Oral Insulin Study Under FDA's Approved Dual Concurrent Protocol

Mar 23, 2021 08:51AM

Mar 23, 2021 07:51AM

Mar 16, 2021 08:28AM

Mar 16, 2021 08:25AM

Jan 27, 2021 09:00AM

Jan 21, 2021 08:28AM

Jan 21, 2021 08:25AM Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Nov 24, 2020 08:13AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All